Serum Thyroglobulin Concentrations and 131I Whole-Body Scan Results in Patients with Differentiated Thyroid Carcinoma After Administration of Recombinant Human Thyroid-Stimulating Hormone

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
FIGURE 1.
Protocol for rhTSH administration and radioiodine scanning procedure for patients on THST (148 MBq [4 mCi] ¹³¹I were administered).
Download figure
Open in new tab
Download powerpoint
FIGURE 2.
Serum TSH concentrations (mean ± SE) at baseline and after rhTSH injections during 5 d of study.
Download figure
Open in new tab
Download powerpoint
FIGURE 3.
Serum Tg levels at baseline and after rhTSH administration in 29 patients of group A (A) and in 4 patients of group B (B).
Download figure
Open in new tab
Download powerpoint
FIGURE 4.
Results of whole-body scanning and Tg measurements after rhTSH administration in 29 patients with baseline Tg levels of <2 ng/mL (group A) on THST.
Download figure
Open in new tab
Download powerpoint
FIGURE 5.
Results of whole-body scanning and Tg measurements after rhTSH administration in 4 patients with baseline Tg levels of >2 ng/mL (group B) on THST.

TABLE 1

Tumor Characteristics, Serum Tg Concentrations, and ¹³¹I WBS in 33 DTC Patients Before Study

Group*	Patient no.	Histology	TNM classification^†	¹³¹I dose^‡ (kBq)	¹³¹I WBS uptake	Baseline Tg on THST^§
A	1	P/i	T4N0M0	3.7 (100)	T^¶	0.9
	2	P	T3N0M0	3.7 (100)	T^¶	<0.9
	3	P	T4N1M1	3.7 (100)	M, L^¶	1.5
	4	P	T4N1M0	3.7 (100)	T^¶	1.2
	5	P	T4N0M0	3.7 (100)	T^¶	<0.9
	6	P/f	T4N1M1	3.7 (100)	L^¶	<0.9
	7	P/i	T2N0M1	3.7 (100)	T, L^¶	<0.9
	8	P	T4N0M0	3.7 (100)	T^¶	<0.9
	9	P/f	T2N0M0	0.18 (5)	T^∥	<0.9
	10	P	T1N0M0	0.18 (5)	0^∥	<0.9
	11	P	T1N0M0	0.18 (5)	0^∥	<0.9
	12	P	T2N0M0	0.18 (5)	0^∥	<0.9
	13	P	T3N0M0	0.18 (5)	0^∥	<0.9
	14	P	T1N0M0	0.18 (5)	0^∥	<0.9
	15	P	T1N0M0	0.18 (5)	0^∥	<0.9
	16	P	T1N0M0	0.18 (5)	T^∥	<0.9
	17	P	T1N0M0	0.18 (5)	T^∥	<0.9
	18	P	T4N1M0	0.18 (5)	0^∥	<0.9
	19	P	T2N0M0	0.18 (5)	0^∥	<0.9
	20	P	T3N0M0	0.18 (5)	T^∥	<0.9
	21	P	T2N0M0	0.18 (5)	0^∥	<0.9
	22	P	T3N1M0	0.18 (5)	0^∥	<0.9
	23	P	T2N1M0	0.18 (5)	T^∥	<0.9
	24	P	T1N0M0	0.18 (5)	0^∥	<0.9
	25	P/i	T3N0M0	0.18 (5)	0^∥	<0.9
	26	P	T2N0M0	0.18 (5)	0^∥	<0.9
	27	P	T2N0M0	0.18 (5)	0^∥	<0.9
	28	P/f	T2N0M0	0.18 (5)	0^∥	<0.9
	29	P	T1N0M0	0.18 (5)	T^∥	<0.9
B	30	P	T4N1M1	7.4 (200)	T, L^¶	17
	31	P	T4N1M1	7.4 (200)	T, M, L^¶	12
	32	P/f	T2N1M1	7.4 (200)	L^¶	5.3
	33	F	T4N0M1	7.4 (200)	B^¶	35

↵*Group A = patients with Tg of <2 ng/mL on THST; group B = patients with Tg of >2 ng/mL on THST.
↵^†TNM classification from (28).
↵^‡¹³¹I (kBq; mCi in parentheses) administered 72–96 h before WBS.
↵^§Serum Tg concentrations measured 6–24 mo after diagnostic or therapeutic ¹³¹I WBS.
↵^¶Posttherapy WBS performed 6–12 mo before study.
↵^∥Diagnostic WBS performed 6–24 mo before study.
¹³¹I WBS = whole-body scanning; P/i = insular variant of papillary carcinoma; T = thyroid bed uptake; P = papillary carcinoma; M = mediastinal uptake; L = lung uptake; P/f = follicular variant of papillary carcinoma; 0 = no uptake; F = follicular carcinoma; B = bone uptake.